149 related articles for article (PubMed ID: 36104946)
1. Hepatocyte-targeting and tumor microenvironment-responsive liposomes for enhanced anti-hepatocarcinoma efficacy.
Cheng D; Wen Z; Chen H; Lin S; Zhang W; Tang X; Wu W
Drug Deliv; 2022 Dec; 29(1):2995-3008. PubMed ID: 36104946
[TBL] [Abstract][Full Text] [Related]
2. A safe and efficient hepatocyte-selective carrier system based on myristoylated preS1/21-47 domain of hepatitis B virus.
Zhang Q; Zhang X; Chen T; Wang X; Fu Y; Jin Y; Sun X; Gong T; Zhang Z
Nanoscale; 2015; 7(20):9298-310. PubMed ID: 25945919
[TBL] [Abstract][Full Text] [Related]
3. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.
Tang J; Wang Q; Yu Q; Qiu Y; Mei L; Wan D; Wang X; Li M; He Q
Acta Biomater; 2019 Jan; 83():379-389. PubMed ID: 30395963
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
Li J; Xu H; Ke X; Tian J
J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
[TBL] [Abstract][Full Text] [Related]
5. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.
Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J
Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363
[No Abstract] [Full Text] [Related]
6. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells.
Zhang X; Zhang Q; Peng Q; Zhou J; Liao L; Sun X; Zhang L; Gong T
Biomaterials; 2014 Jul; 35(23):6130-41. PubMed ID: 24797877
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
8. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.
Zhu L; Kate P; Torchilin VP
ACS Nano; 2012 Apr; 6(4):3491-8. PubMed ID: 22409425
[TBL] [Abstract][Full Text] [Related]
10. Hydroxycamptothecin liposomes based on thermal and magnetic dual-responsive system: preparation, in vitro and in vivo antitumor activity, microdialysis-based tumor pharmacokinetics.
Zhu HM; Gu JH; Xie Y; Xie B; Ling JJ
J Drug Target; 2018 Apr; 26(4):345-356. PubMed ID: 28920483
[TBL] [Abstract][Full Text] [Related]
11. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
13. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
Tian J; Wang L; Wang L; Ke X
Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357
[TBL] [Abstract][Full Text] [Related]
14. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
[TBL] [Abstract][Full Text] [Related]
15. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
[TBL] [Abstract][Full Text] [Related]
16. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
17. Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide.
Witzigmann D; Uhl P; Sieber S; Kaufman C; Einfalt T; Schöneweis K; Grossen P; Buck J; Ni Y; Schenk SH; Hussner J; Meyer Zu Schwabedissen HE; Québatte G; Mier W; Urban S; Huwyler J
Elife; 2019 Jul; 8():. PubMed ID: 31333191
[TBL] [Abstract][Full Text] [Related]
18. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
[TBL] [Abstract][Full Text] [Related]
19. Co-Delivery of Curcumin and Capsaicin by Dual-Targeting Liposomes for Inhibition of aHSC-Induced Drug Resistance and Metastasis.
Qi C; Wang D; Gong X; Zhou Q; Yue X; Li C; Li Z; Tian G; Zhang B; Wang Q; Wei X; Wu J
ACS Appl Mater Interfaces; 2021 Apr; 13(14):16019-16035. PubMed ID: 33819006
[TBL] [Abstract][Full Text] [Related]
20. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
